Novo Nordisk seeks U.S., European approval of diabetes drug

05/27/2008 | Bloomberg

Danish firm Novo Nordisk A/S is seeking marketing approval for diabetes treatment liraglitude in the U.S. and Europe in a bid to launch the drug next year. Liraglitude is expected to compete with similar drugs being developed by Sanofi-Aventis and Novartis. The drug is based on glucagon-like peptide-1, a hormone that activates insulin production in the pancreas.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX